Summary
Enzyme-linked immunosorbent assay (ELISA) methods and immunohistochemistry (IHC) are techniques that provide information on protein expression in tissue samples. Both methods have been used to investigate the impact of the plasminogen activation (PA) system in cancer. In the present paper we first compared the expression levels of uPA, tPA, PAI-1 and uPAR in a compound group consisting of 33 cancer lesions of various origin (breast, lung, colon, cervix and melanoma) as quantitated by ELISA and semi-quantitated by IHC. Secondly, the same kind of comparison was performed on a group of 23 melanoma lesions and a group of 28 breast carcinoma lesions. The two techniques were applied to adjacent parts of the same frozen tissue sample, enabling the comparison of results obtained on material of almost identical composition. Spearman correlation coefficients between IHC results and ELISA results for uPA, tPA, PAI-1 and uPAR varied between 0.41 and 0.78, and were higher for the compound group and the breast cancer group than for the melanoma group. Although a higher IHC score category was always associated with an increased median ELISA value, there was an overlap of ELISA values from different scoring classes. Hence, for the individual tumour cases the relation between ELISA and IHC is ambiguous. This indicates that the two techniques are not directly interchangeable and that their value for clinical purposes may be different.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andreasen, P. A., Kjøller, L., Christensen, L. & Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22.
Behrendt, N., Rønne, E., Ploug, M., Petri, T., Løber, D., Nielsen, L. S., Schleuning, W-D, Blasi, F., Appella, E. & Danø, K. (1990). The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 265: 6453–6460.
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
Christensen, L., Wiborg Simonsen, A. C., Heegaard, C. W., Moestrup, S. K., Andersen, J. A. & Andreasen, P. A. (1996). Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441–452.
de Vries, T. J., van Muijen, G. N. P. & Ruiter, D. J. (1996). The plasminogen activation system in tumour invasion and metastasis. Path Res Pract 192: 718–733.
de Witte, H., Pappot, H., Brünner, N., Grøndahl-Hansen, J., Høyer-Hansen, G., Behrendt, N., Guldhammer-Skov, B., Sweep, F., Benraad, T. & Danø, K. (1997). ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts. Int J Cancer 72: 416–423.
Duggan, C., Maguire, T., McDermott, E., O’Higgins, N., Fennelly, J. J. & Duffy, M. J. (1995). Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597–600.
Ferrier, C. M., van Geloof, W. L., de Witte, J. H., Kramer, M. D., Ruiter, D. J. & van Muijen, G. N. P. (1998). Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J Histochem Cytochem 46: 469–476.
Foekens, J. A., Buessecker, F., Peters, H. A., Krainick, U., van Putten, W. L. J., Look, M. P., Klijn, J. G. M. & Kramer, M. D. (1995). Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423–1427.
Ganesh, S., Sier, C. F. M., Heerding, M. M., van Krieken, J.H.J.M., Griffioen, G., Welvaart, K., van de Velde, C. J. H., Verheijen, J. H., Lamers, C.B.H.W. & Verspaget, H. W. (1996). Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 77: 1035–1043.
Grebenschikov, N., Geurts-Moespot, A., de Witte, H., Heuvel, J., Leake, R., Sweep, F. & Benraad, T. (1997). A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 12: 6–14.
Heiss, M. M., Babic, R., Allgayer, H., Gruetzner, K. U., Jauch, K-W, Loehrs, U. & Schildberg, F. W. (1996). The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur J Surg Oncol 22: 74–77.
Hsu, D. W., Efird, J. T. & Hedley-Whyte, E. T. (1995). Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147: 114–123.
Jänicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gössner, W. & Graeff, H. (1990). Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69–78.
Kobayashi, H., Fujishiro, S. & Terao, T. (1994). Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539–6548.
Kuhn, W., Pache, L., Schmalfeldt, B., Dettmar, P., Schmitt, M., Jänicke, F. & Graeff, H. (1994). Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401–409.
Mulcahy, H. E., Duffy, M. J., Gibbons, D., McCarthy, P., Parfrey, N. A., O’Donoghue, D. P. & Sheahan, K. (1994). Urokinase-type plasminogen activator and outcome in Dukes’ B colorectal cancer. Lancet 344: 583–584.
Pappot, H., Guldhammer Skov, B., Pyke, C. & Grøndahl-Hansen, J. (1997). Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. Lung Cancer 17: 197–209.
Rønne, E., Behrendt, N., Ellis, V., Ploug, M., Danø, K. & Høyer-Hansen, G. (1991). Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 288: 233–236.
Rønne, E., Høyer-Hansen, G., Brünner, N., Pederson, H., Rank, F., Osborne, C. K., Clark, G. M., Danø, K. & Grøndahl-Hansen, J. (1995). Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 33: 199–207.
Ruiter, D. J., Ferrier, C. M., van Muijen, G. N. P., Henzen-Logmans, S. C., Kennedy, S., Kramer, M. D., Nielsen, B. S. & Schmitt, M. (1998). Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. Eur J Cancer 34: 1334–1340.
Schmitt, M., Thomssen, C., Ulm, K., Seiderer, A., Harbeck, N., Höfler, H., Jänicke, F. & Graeff, H. (1997). Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306–311.
Sier, C. F. M., Fellbaum, C., Verspaget, H. W., Schmitt, M., Griffioen, G., Graeff, H., Höfler, H. & Lamers, C.B.H.W. (1991). Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology 19: 231–237.
Sweep, C. G. J., Geurts-Moespot, J., Grebenschikov, N., de Witte, J. H., Heuvel, J.J.T.M., Schmitt, M., Duffy, M. J., Jänicke, F., Kramer, M. D., Foekens, J. A., Brünner, N., Brugal, G., Pedersen, A. N. & Benraad, T. J. (1998). External quality assessment of trans-European multicentre antigen determinations (Enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78: 1434–1441.
Thorpe, S. M. (1987). Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays. Breast Cancer Res Treat 9: 175–189.
Umeda, T., Eguchi, Y., Okino, K., Kodama, M. & Hattori, T. (1997). Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 183: 388–397.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ferrier, C., Witte, H., Straatman, H. et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer 79, 1534–1541 (1999). https://doi.org/10.1038/sj.bjc.6690245
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690245
Keywords
This article is cited by
-
A microfluidic biosensor for the diagnosis of chronic wasting disease
Microsystems & Nanoengineering (2023)
-
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer
Journal of Cancer Research and Clinical Oncology (2020)
-
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
Scientific Reports (2019)
-
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients
Cancer Chemotherapy and Pharmacology (2015)
-
Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease
Alzheimer's Research & Therapy (2014)